Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 201–300 of 2,932
An update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections
Jenks, J. D., White, P. L., Kidd, S. E., Goshia, T., Fraley, S. I., Hoenigl, M., & Thompson, G. R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2267977 · Cited by 61
“Invasive fungal infections (IFDs) cause millions of infections and account for an estimated 1.6 million deaths annually, twice the number of annual deaths caused by HIV/AIDS [1,2] and similar to deaths from tuberculosis [3].”
BackgroundInfluentialΙωάννου, Μ., Hoving, D., Aramburu, I. V., Temkin, M. I., de Vasconcelos, N. M., Tsourouktsoglou, T.-D., Wang, Q., Boeing, S., Goldstone, R. J., Vernardis, S. I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32320-1 · Cited by 75
Pfaller, M. A., Rhomberg, P. R., Wiederhold, N. P., Gibas, C. F. C., Sanders, C. J., Fan, H., Mele, J., Kovanda, L. L., & Castanheira, M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01230-18 · Cited by 68
Janbon, G., Quintin, J., Lanternier, F., & d’Enfert, C. (2019) · Microbes and Infection · doi:10.1016/j.micinf.2019.06.011 · Cited by 74
Bastos, R. W., Valero, C., Silva, L. P., Schoen, T., Drott, M., Brauer, V., Silva-Rocha, R., Lind, A., Steenwyk, J. L., Rokas, A., et al. (2020) · mSphere · doi:10.1128/msphere.00153-20 · Cited by 60
“and is characterized by systemic host invasion, resulting in high mortality rates (30 to 95%) (2, 10, 11).”
Dacrory, S., Hashem, A. H., & Hasanin, M. S. (2021) · Environmental Nanotechnology Monitoring & Management · doi:10.1016/j.enmm.2021.100453 · Cited by 80
Singh, A., Singh, K., Sharma, A., Kaur, K., Chadha, R., & Bedi, P. M. S. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14266 · Cited by 71
“10 Candidal pancreatitis Pancreas Chakrabarti et al. (2007) T A B L E 1 Major human fungal”
BackgroundCandida albicans at Host Barrier Sites: Pattern Recognition Receptors and Beyond
Swidergall, M. (2019) · Pathogens · doi:10.3390/pathogens8010040 · Cited by 59
“The oral cavity hosts up to 100 different fungal species [82], and the epithelial barrier is able to discriminate between commensal and pathogenic fungal forms [83].”
BackgroundHigh‐Throughput Gene Replacement in Aspergillus fumigatus
Zhao, C., Fraczek, M. G., Dineen, L., Lebedinec, R., Macheleidt, J., Heinekamp, T., Delneri, D., Bowyer, P., Brakhage, A. A., & Bromley, M. (2019) · Current Protocols in Microbiology · doi:10.1002/cpmc.88 · Cited by 62
“A further 200,000 individuals are believed to be affected by invasive aspergillosis every year (Bongomin et al., 2017).”
BackgroundEvaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
Kapoor, M., Moloney, M., Soltow, Q. A., Pillar, C. M., & Shaw, K. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01387-19 · Cited by 59
“5 million people worldwide annually (1, 2).”
Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes
Qadri, H., Shah, A. H., & Mir, M. A. (2020) · Current Drug Targets · doi:10.2174/1389450121666201228123212 · Cited by 76
Lamon, G., Lends, A., Valsecchi, I., Wong, S. S. W., Duprès, V., Lafont, F., Tolchard, J., Schmitt, C., Mallet, A., Grélard, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2212003120 · Cited by 58
“Due to a limited number of antifungal drugs available for clinical treatment (2, 5) and the emergence of drug resistance (6), Aspergillus fumigatus is still highly recalcitrant to most antifungal strategies.”
Understanding the mechanisms of resistance to azole antifungals in Candida species
Li, Y., Hind, C. K., Furner-Pardoe, J., Sutton, J. M., & Rahman, K. M. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf106 · Cited by 79
Shourian, M., & Qureshi, S. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00066 · Cited by 64
“In a similar manner, tissue damage control can also occur through various mechanisms that (1) enforce barrier function of epithelial cells and prevent pathogen access to host tissue, (2) neutralize pathogen toxins and virulence factors, (3) regulate the intensity and duration of the host immune and inflammatory respon…”
BackgroundInfluentialLactoferrin Is Broadly Active against Yeasts and Highly Synergistic with Amphotericin B
Fernandes, K. E., Weeks, K., & Carter, D. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02284-19 · Cited by 66
“albicans (12–14), and synergistic interactions between azoles and the LF peptides lactoferricin and LF(1-11) have been observed (37).”
BackgroundMethodGarg, A. K., Maddiboyina, B., Alqarni, M. H., et al. (2021) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2021.1892471 · Cited by 59
Anti-fungal properties and mechanisms of melittin
Memariani, H., & Memariani, M. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10701-0 · Cited by 58
Shivarathri, R., Tscherner, M., Zwolanek, F., Singh, N. K., Chauhan, N., & Kuchler, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-45817-5 · Cited by 58
The potential role of plant secondary metabolites on antifungal and immunomodulatory effect
Zhou, X., Zeng, M., Huang, F., Qin, G., Song, Z., & Liu, F. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12601-5 · Cited by 82
Clark, C., & Drummond, R. (2019) · Pathogens · doi:10.3390/pathogens8020045 · Cited by 58
Nobre, F. X., Bastos, I. D. S., Fontenelle, R. O. D. S., Júnior, E. A. A., Takeno, M. L., Manzato, L., de Matos, J. M. E., Orlandi, P. P., Mendes, J. D. F. S., Brito, W. R., et al. (2019) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2019.104620 · Cited by 58
Thornton, C. R. (2019) · Advances in applied microbiology · doi:10.1016/bs.aambs.2019.10.003 · Cited by 71
Monocytes and the Host Response to Fungal Pathogens
Heung, L. J. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00034 · Cited by 66
Fontaine, T., & Latgé, J. (2020) · Journal of Fungi · doi:10.3390/jof6040283 · Cited by 63
“Global multinational prevalence of aspergillosis reaches an estimated 3,000,000 cases per year of chronic pulmonary aspergillosis and 250,000 cases per year of invasive aspergillosis [1].”
BackgroundCarbon nanostructures: a comprehensive review of potential applications and toxic effects
Farmand, M., Jahanpeyma, F., Gholaminejad, A., Azimzadeh, M., Malaei, F., & Shoaie, N. (2022) · 3 Biotech · doi:10.1007/s13205-022-03175-6 · Cited by 62
“According to recent reports, fungal infections are a significant challenging threat to human health that commonly arise as a consequence of other health problems such as acquired immunodeficiency syndrome (AIDS), organ transplantation, cancer, asthma, corticosteroid therapies, and individuals with the weak immune syst…”
BackgroundLiu, F., Chen, Y., Huang, Y., Li, Y., Lu, Z., Han, H., Song, X., Jin, Q., & Ji, J. (2024) · Nature Communications · doi:10.1038/s41467-024-53410-2 · Cited by 74
Menacing Mold: Recent Advances in Aspergillus Pathogenesis and Host Defense
Tischler, B. Y., & Hohl, T. M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.03.027 · Cited by 60
“Despite contemporary antifungal drugs, an estimated 200,000 cases of IA occur globally [5], with fungusattributable mortality rates that exceed 20% in patients with hematologic malignancies and in allogeneic hematopoietic cell transplants [6].”
BackgroundDong, P., Zong, C., Dagher, Z., Hui, J., Li, J., Zhan, Y., Zhang, M., Mansour, M. K., & Cheng, J. (2021) · Science Advances · doi:10.1126/sciadv.abd5230 · Cited by 60
Phloroglucinol and Its Derivatives: Antimicrobial Properties toward Microbial Pathogens
Khan, F., Tabassum, N., Bamunuarachchi, N. I., & Kim, Y. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c00532 · Cited by 59
A secondary mechanism of action for triazole antifungals in Aspergillus fumigatus mediated by hmg1
Rybak, J. M., Xie, J., Martín‐Vicente, A., Guruceaga, X., Thorn, H. I., Nywening, A. V., Ge, W., Souza, A. C. O., Shetty, A. C., McCracken, C. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48029-2 · Cited by 59
“Even with timely diagnosis and administration of appropriate antifungal therapy, the mortality rates for IAoften exceed 50% 1 .”
InfluentialThe effect of antifungal resistance development on the virulence of Candida species
Bohner, F., Papp, C., & Gácser, A. (2022) · FEMS Yeast Research · doi:10.1093/femsyr/foac019 · Cited by 83
“are among the most prominent causes of fungal infections (Bongomin et al. 2017).”
BackgroundInfluentialSalazar, S. B., Simões, R., Pedro, N. A., Pinheiro, M. J. F., Carvalho, M. F. N. N., & Mira, N. P. (2020) · Journal of Fungi · doi:10.3390/jof6010023 · Cited by 63
“The incidence of invasive candidiasis annually is estimated to be 700,000 infections, with associated mortality rates close to 50%, especially in countries where no adequate antifungal therapy is available [1,2].”
BackgroundImmunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies
Boniche-Alfaro, C., Rossi, S. A., Kischkel, B., Barbalho, F. V., Moura, Á. N. D., Nosanchuk, J. D., Travassos, L. R., & Taborda, C. P. (2020) · Journal of Fungi · doi:10.3390/jof6010031 · Cited by 64
“The toxicity of these medications is an important limitation to their use [4,10,24] and, in order to avert the universal failure in the management of fungal infections, new therapeutic strategies to treat systemic fungal infections are urgently needed [24,25].”
BackgroundWijesinghe, G. K., Maia, F. C., de Oliveira, T. R., de Feiria, S. N. B., Jóia, F., Barbosa, J. P., Boni, G. C., Sardi, J. D. C. O., Rosalen, P. L., & Höfling, J. F. (2020) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760200349 · Cited by 63
“13% of these were reported with patients with underlying predisposing factor like compromised immunity etc.(10,11) Among all Candida species, Candida albicans is the most frequent etiological agent in cases of fungal infections, being associated in up to 50% of cases of this disease.”
Backgroundde Aguiar, F. L. L., Santos, N. C., Cavalcante, C. S. D. P., Andreu, D., Rádis‐Baptista, G., & Gonçalves, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218339 · Cited by 64
“5 million deaths each year worldwide [21].”
Lewandowska, A., Soutar, C. P., Greenwood, A. I., Nimerovsky, E., Lio, A. M. D., Holler, J. T., Hisao, G. S., Khandelwal, A., Zhang, J., SantaMaria, A. M., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00685-4 · Cited by 55
The Toll pathway mediates Drosophila resilience to Aspergillus mycotoxins through specific Bomanins
Xu, R., Lou, Y., Tidu, A., Bulet, P., Heinekamp, T., Martin, F., Brakhage, A. A., Li, Z., Liégeois, S., & Ferrandon, D. (2022) · EMBO Reports · doi:10.15252/embr.202256036 · Cited by 51
“Fungal infections represent a widespread major health threat worldwide affecting more than 150 million patients and cause directly or indirectly at least one and a half million of deaths each year (Bongomin et al., 2017; Rodrigues and Nosanchuk, 2020).”
A B1a–natural IgG–neutrophil axis is impaired in viral- and steroid-associated aspergillosis
Sarden, N., Sinha, S., Potts, K. G., Pernet, E., Hiroki, C. H., Hassanabad, M. F., Nguyen, A., Lou, Y., Farias, R., Winston, B. W., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq6682 · Cited by 53
Martins‐Santana, L., Rezende, C. P., Rossi, A., Martinez-Rossi, N. M., & Almeida, F. B. D. R. (2023) · Pathogens · doi:10.3390/pathogens12020293 · Cited by 66
“Keratitis rates were considerably higher in countries such as Nepal, Pakistan, Thailand, Egypt, and Mexico [2].”
BackgroundInfluentialWhat are the 100 most cited fungal genera?
Bhunjun, C. S., Chen, Y. J., Phukhamsakda, C., Boekhout, T., Groenewald, J. Z., McKenzi, E. H. C., Francisco, E. C., Frisvad, J. C., Groenewald, M., Hurdeal, V. G., et al. (2024) · Studies in Mycology · doi:10.3114/sim.2024.108.01 · Cited by 77
Ketoconazole-p-aminobenzoic Acid Cocrystal: Revival of an Old Drug by Crystal Engineering
Martin, F., Pop, M. M., Kacsó, I., Grosu, I., Miclaus, M. O., Vodnar, D. C., Lung, I., Filip, G. A., Olteanu, D. E., Moldovan, R., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01178 · Cited by 61
Amich, J., Mokhtari, Z., Strobel, M., Vialetto, E., Sheta, D., Yu, Y., Hartweg, J., Kalleda, N., Jarick, K. J., Brede, C., et al. (2020) · mBio · doi:10.1128/mbio.02752-19 · Cited by 62
“fumigatus is the most prominent fungal pathogen of the human lung and is responsible for an estimated incidence of more than 300,000 cases of invasive aspergillosis, a lethal disease that causes 150,000 deaths annually (3).”
BackgroundBaghel, S. S., Nair, V. S., Pirani, A., Sravani, A. B., Bhemisetty, B., Koteshwara, A., Aranjani, J. M., & Lewis, S. A. (2020) · Dermatologic Therapy · doi:10.1111/dth.13959 · Cited by 64
“Patients undergoing chemotherapy or those who are immunocompromised, are prone to fungal infections.(5) Several factors such as socio-economic and geographical changes, improper use of broad spectrum antibiotics, excessive use of corticosteroids and emerging problems of resistance towards antifungal agents contribute…”
BackgroundCarolis, E. D., Marchionni, F., Torelli, R., Morandotti, G. A., Pagano, L., Murri, R., PASCALE, G. D., Angelis, G. D., Sanguinetti, M., & Posteraro, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236095 · Cited by 54
Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox
Kane, A., & Carter, D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040482 · Cited by 58
“also remain a pressing concern, together causing an estimated 400,000 deaths per year, with chronic pulmonary aspergillosis severely affecting close to 3 million people [2].”
BackgroundGarvey, M., Meade, E., & Rowan, N. J. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.158284 · Cited by 64
“Despite the fact that problematical fungi infect billions of people annually, there is a signi fi cant under appreciation of their aetiological contribution to worldwide diseases (Bongomin et al., 2017).”
BackgroundPotential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review
Rabaan, A. A., Sulaiman, T., Al-Ahmed, S. H., Buhaliqah, Z. A., Buhaliqah, A. A., AlYuosof, B., Alfaresi, M. S., Fares, M. A. A., Alwarthan, S. M., Alkathlan, M. S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030608 · Cited by 66
“For instance, recent studies estimated ~300,000 cases of invasive Aspergillosis, 750,000 cases of Candidiasis, and more than 900,000 cases of Mucormycosis infection annually [6,7].”
BackgroundWaghule, T., Sankar, S., Rapalli, V. K., Gorantla, S., Dubey, S. K., Chellappan, D. K., Dua, K., & Singhvi, G. (2020) · Dermatologic Therapy · doi:10.1111/dth.13905 · Cited by 67
“This is more than 80% of the current world population.(1) According to the 2013 Global Burden of”
Backgroundvan Rhijn, N., Furukawa, T., Zhao, C., McCann, B. L., Bignell, E., & Bromley, M. (2020) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2020.103479 · Cited by 47
“fumigatus also causes chronic and allergic diseases in immunocompetent individuals which affects around 3 million and 20 million people, respectively (Bongomin et al. 2017).”
BackgroundHodges, M. R., Ople, E., Wedel, P., Shaw, K. J., Jakate, A., Kramer, W. G., Marle, S. V., van Hoogdalem, E.-J., & Tawadrous, M. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01623-22 · Cited by 52
Ramos-Inza, S., Plano, D., & Sanmartín, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114834 · Cited by 58
Abdelgalil, M. H., Ammar, Y. A., Ali, G. A. M. E., Ali, A. K., & Ragab, A. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134443 · Cited by 56
Recent gene selection and drug resistance underscore clinical adaptation across Candida species
Schikora-Tamarit, M. À., & Gabaldón, T. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01547-z · Cited by 59
Fungal infections in immunocompromised critically ill patients
Garnacho-Montero, J., Barrero-García, I., & León-Moya, C. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.01.005 · Cited by 56
“[ 2 ] Acute respiratory failure (ARF) is the leading cause of intensive care unit (ICU) admissions among immunocompromised patients, and the vast majority of them are due to respiratory infections.”
BackgroundDao, A., Kim, H. Y., Garnham, K., Kidd, S. E., Sati, H. F., Perfect, J. R., Sorrell, T. C., Harrison, T. S., Rickerts, V., Gigante, V., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae043 · Cited by 79
Lung colonization by Aspergillus fumigatus is controlled by ZNF77
Gago, S., Overton, N. L. D., Ben-Ghazzi, N., Novak-Frazer, L., Read, N. D., Denning, D. W., & Bowyer, P. (2018) · Nature Communications · doi:10.1038/s41467-018-06148-7 · Cited by 51
Self-citationEmerging Animal-Associated Fungal Diseases
Carpouron, J. E., de Hoog, S., Gentekaki, E., & Hyde, K. D. (2022) · Journal of Fungi · doi:10.3390/jof8060611 · Cited by 58
“Approximately 500,000 people suffer from histoplasmosis annually, 100,000 develop disseminated histoplasmosis and 25,000 die from the disease [1].”
BackgroundAntifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives
Branda, F., Petrosillo, N., Ceccarelli, G., Giovanetti, M., VITO, A. D., Madeddu, G., Scarpa, F., & Ciccozzi, M. (2025) · Infectious Disease Reports · doi:10.3390/idr17040091 · Cited by 86
“In addition, their availability remains limited in many low-income countries [112].”
Burden of Fungal Infections in Colombia
Álvarez, C., Cortés, J. A., & Denning, D. W. (2018) · Journal of Fungi · doi:10.3390/jof4020041 · Cited by 57
“No local reports on the incidence, prevalence, or burden of the problem have been found, despite the fact that according to worldwide epidemiology, these are the most frequently found fungal infections [62].”
BackgroundInfluentialSelf-citationInnate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
“6 million people per annum (3); comparable to tuberculosis and more than 3-fold higher than malaria.”
BackgroundLakoh, S., Kamudumuli, P. S., Penney, R. O. S., Haumba, S., Jarvis, J. N., Hassan, A. J., Moudoute, N. L. E., Ocansey, B. K., Izco, S., Kipkerich, S., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00656-9 · Cited by 52
“13,14 In the past decade, rapid diagnostic methods for fungal infections have been developed and put on the market.”
BackgroundSelf-citationHumans vs. Fungi: An Overview of Fungal Pathogens against Humans
Thambugala, K. M., Daranagama, D. A., Tennakoon, D. S., Jayatunga, D. P. W., Hongsanan, S., & Xie, N. (2024) · Pathogens · doi:10.3390/pathogens13050426 · Cited by 83
“Fungi are responsible for 1.5 million annual fatalities and have infected one-third of the human population [3,4,7–9].”
InfluentialBongomin, F., Kwizera, R., & Denning, D. W. (2019) · Journal of Fungi · doi:10.3390/jof5030080 · Cited by 49
“The true burden of HIV-associated disseminated histoplasmosis remains unknown since it is not a notifiable disease [17].”
BackgroundSelf-citationRokas, A., Mead, M. E., Steenwyk, J. L., Oberlies, N. H., & Goldman, G. H. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008315 · Cited by 50
Prevalence and Therapeutic Challenges of Fungal Drug Resistance: Role for Plants in Drug Discovery
Marquez, L., & Quave, C. L. (2020) · Antibiotics · doi:10.3390/antibiotics9040150 · Cited by 63
“While dermatophytes do not often cause life-threatening infections, their prevalence among the population has been estimated at nearly one billion cases globally [15].”
BackgroundProgrammed Cell Death: Central Player in Fungal Infections
Camilli, G., Blagojevic, M., Naglik, J. R., & Richardson, J. P. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.11.005 · Cited by 60
“The high incidence of fungal infections is largely attributable to an increase in the number of immunocompromised individuals, including HIV/AIDS patients, cancer patients, and organ transplant recipients [3,4].”
BackgroundBuil, J. B., Oliver, J. D., Law, D., Baltussen, T. J. H., Zoll, J., Hokken, M., Tehupeiory-Kooreman, M. C., Melchers, W. J. G., Birch, M., & Verweij, P. E. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2034485 · Cited by 52
Kahlfuß, S., Kaufmann, U., Concepcion, A. R., Noyer, L., Raphael, D., Vaeth, M., Yang, J., Pancholi, P., Maus, M., Muller, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911592 · Cited by 52
“Over 150 million people worldwide are estimated to suffer from fungal diseases, with the severity ranging from asymptomatic-mild to life-threatening systemic infections resulting in ~1.6 million deaths associated with fungal disease each year (Bongomin et al, 2017).”
BackgroundInfluentialProfiling of Antifungal Activities and In Silico Studies of Natural Polyphenols from Some Plants
Khanzada, B., Akhtar, N., Okla, M. K., Alamri, S. A., Al-Hashimi, A., Baig, M. W., Rubnawaz, S., AbdElgawad, H., Hirad, A. H., Haq, I., et al. (2021) · Molecules · doi:10.3390/molecules26237164 · Cited by 49
“Fungal infections are continuously on the rise and one of the major causes of morbidity and mortality, particularly in immune-compromised patients [1,2].”
BackgroundParker, R. A., Gabriel, K. T., Graham, K., Butts, B. K., & Cornelison, C. T. (2022) · Pathogens · doi:10.3390/pathogens11080821 · Cited by 61
“Low and Rotstein observed a threefold increase in deaths from invasive fungal infections between 1981 and 1996 [2], and current estimates place the global incidence of several invasive fungal infections at 1,000,000 cases or more each year (Table 1) [3].”
BackgroundNguyen, T. A., Kim, H. Y., STOCKER, S. L., Kidd, S. E., Alastruey‐Izquierdo, A., Dao, A., Harrison, T. S., Wahyuningsih, R., Rickerts, V., Perfect, J. R., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myad132 · Cited by 70
Self-citationMartian, P. C., Tertiş, M., Leonte, D., Hădade, N. D., Cristea, C., & Crisan, O. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116488 · Cited by 62
Synthesis of N-substituted indole derivatives as potential antimicrobial and antileishmanial agents
Tiwari, S., Kirar, S., Banerjee, U. C., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103787 · Cited by 49
Tratrat, C. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200704140107 · Cited by 54
Mba, I. E., & Nweze, E. I. (2020) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-020-02940-0 · Cited by 54
Post-Translational Modifications Drive Success and Failure of Fungal–Host Interactions
Retanal, C., Ball, B., & Geddes‐McAlister, J. (2021) · Journal of Fungi · doi:10.3390/jof7020124 · Cited by 56
“Fungal pathogens are critical threats to global health, with more than 300 million people afflicted with serious fungal diseases annually [6].”
BackgroundCandida albicans Induces Cross-Kingdom miRNA Trafficking in Human Monocytes To Promote Fungal Growth
Halder, L. D., Babych, S., Palme, D. I., Mansouri-Ghahnavieh, E., Ivanov, L., Ashonibare, V. J., Langenhorst, D., Prusty, B. K., Rambach, G., Wich, M., et al. (2022) · mBio · doi:10.1128/mbio.03563-21 · Cited by 56
A Comprehensive Update on the Bioactive Compounds from Seagrasses
Gono, C. M. P., Ahmadi, P., Hertiani, T., Septiana, E., Putra, M. Y., & Chianese, G. (2022) · Marine Drugs · doi:10.3390/md20070406 · Cited by 60
Estimated Burden of Serious Fungal Infections in Ghana
Ocansey, B. K., Pesewu, G. A., Codjoe, F. S., Osei-Djarbeng, S. N., Feglo, P. K., & Denning, D. W. (2019) · Journal of Fungi · doi:10.3390/jof5020038 · Cited by 54
“that global estimates of SFI’s found 500,000 cases of PCP in AIDS and non-AIDS people around the world [97].”
BackgroundResultSelf-citationFungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors
Zarakas, M. A., Desai, J. V., Chamilos, G., & Lionakis, M. S. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00343-9 · Cited by 52
Knowles, S. L., Mead, M. E., Silva, L. P., Raja, H. A., Steenwyk, J. L., Goldman, G. H., Rokas, A., & Oberlies, N. H. (2020) · mBio · doi:10.1128/mbio.03361-19 · Cited by 52
“Aspergillus fumigatus is a major fungal pathogen responsible for hundreds of thousands of infections and deaths each year (1, 2).”
BackgroundSzerencsés, B., Igaz, N., Tóbiás, Á., Prucsi, Z., Rónavári, A., Bélteky, P., Madarász, D., Papp, C., Makra, I., Vágvölgyi, C., et al. (2020) · BMC Microbiology · doi:10.1186/s12866-020-01858-9 · Cited by 52
Heme-iron acquisition in fungi
Roy, U., & Kornitzer, D. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.05.006 · Cited by 45
Ratitong, B., & Pearlman, E. M. (2021) · Current Opinion in Microbiology · doi:10.1016/j.mib.2021.07.018 · Cited by 52
Mamali, V., Siopi, M., Charpantidis, S., Samonis, G., Tsakris, A., Vrioni, G., & on behalf of the Candi-Candi Network (2022) · Journal of Fungi · doi:10.3390/jof8020116 · Cited by 57
“0/100,000 inhabitants [27], while differences may also occur within regions of the same country and between populations at risk [28,29].”
BackgroundFungal infections and the fungal microbiome in hepatobiliary disorders
Hartmann, P., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.12.006 · Cited by 56
Azole resistance in Aspergillus fumigatus- comprehensive review
Dladla, M., Gyzenhout, M., Marais, G. J., & Ghosh, S. (2024) · Archives of Microbiology · doi:10.1007/s00203-024-04026-z · Cited by 50
“It has been estimated that the mortality rate owing to inva - sive fungal infections is comparable to that of TB and three times that of malaria, however, people do not think of fungal illnesses in the same manner (Bongomin et al. 2017 ).”
Friggeri, L., Hargrove, T. Y., Wawrzak, Z., Blobaum, A. L., Rachakonda, G., Lindsley, C. W., Villalta, F., Nes, W. D., Botta, M., Guengerich, F. P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00641 · Cited by 51
de Carvalho, J. A., Hagen, F., Fisher, M. C., Camargo, Z. P. D., & Rodrigues, A. M. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008330 · Cited by 52
“The global burden of sporotrichosis is>40,000 cases [18], and the regions where the disease is endemic include Latin America (especially Brazil, Colombia, Mexico, Peru, and Venezuela) [19], Asia (especially China, India, and Japan) [20] and Africa [21].”
BackgroundCoste, A., Frérou, A., Raute, A., Couturaud, F., Morin, J., Egreteau, P.-Y., Blanc, F.-X., Reignier, J., Tadié, J.-M., Tran, A., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004861 · Cited by 46
“The large ranges of IPA frequency across countries reported worldwide might be due to geographical factors (24).”
BackgroundMba, I. E., Nweze, E. I., Eze, E. A., & Anyaegbunam, Z. K. G. (2022) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2022.105256 · Cited by 46
Castelo‐Branco, D. D. S. C. M., Lockhart, S. R., Chen, Y., Santos, D. A., Hagen, F., Hawkins, N. J., Lavergne, R., Meis, J. F. G. M., Pape, P. L., Rocha, M. F. G., et al. (2021) · Mycoses · doi:10.1111/myc.13404 · Cited by 55
Chakrabarti, A., Mohamed, N., Capparella, M. R., Townsend, A., Sung, A., Yura, R., & Muñóz, P. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac234 · Cited by 48
Parslow, B. Y., & Thornton, C. R. (2022) · Microorganisms · doi:10.3390/microorganisms10061208 · Cited by 59
Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019
Rayens, E. A., Rayens, M. K., & Norris, K. A. (2022) · Emerging infectious diseases · doi:10.3201/eid2810.220391 · Cited by 54
“F pathogens cause millions of deaths and tens of millions of infections globally every year (1).”
BackgroundAntifungal therapy: Novel drug delivery strategies driven by new targets
Wu, S., Song, R., Liu, T., & Li, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114967 · Cited by 57
Ludwig, D. B., de Camargo, L. E. A., Khalil, N. M., Auler, M. E., & Mainardes, R. M. (2018) · Mycopathologia · doi:10.1007/s11046-018-0253-x · Cited by 51
“In recent years, the rate of fungal infections has increased [7] and leads to resistance to antifungal agents [8].”
Shi, X., Cordero, T., Garrigues, S., Marcos, J. F., Daròs, J., & Coca, M. A. (2018) · Plant Biotechnology Journal · doi:10.1111/pbi.13038 · Cited by 48
“More people die every year from fungal infections than from malaria (Bongomin et al., 2017).”
BackgroundA Cyp51B Mutation Contributes to Azole Resistance in Aspergillus fumigatus
González-Jiménez, I., Lucio, J., Amich, J., Cuesta, I., Arroyo, R. S., Alcázar‐Fuoli, L., & Mellado, E. (2020) · Journal of Fungi · doi:10.3390/jof6040315 · Cited by 50
“Among them, invasive aspergillosis (IA) is the most lethal fungal infection caused by this mold, affecting over 300,000 people a year, with a mortality rate ranging from 30–80% [2].”
BackgroundIn vitroinfection models to study fungal–host interactions
Last, A., Maurer, M., Mosig, A. S., Gresnigt, M. S., & Hube, B. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab005 · Cited by 49
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.